Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts expected across vormatrigine, relutrigine and elsunersen in 2026 Strong balance sheet, with $1.5 billion in pro forma cash and investments Combined peak revenue estimates for the four late-stage assets expected to exceed $20 billion BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medici ...